Overview

Combination Chemotherapy Regimens in Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Status:
Completed
Trial end date:
2013-01-10
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving the drugs in different combinations may kill more tumor cells. It is not yet known which combination chemotherapy regimen is more effective in treating ovarian epithelial, primary peritoneal, or fallopian tube cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIB, stage III, or stage IV ovarian epithelial cancer , primary peritoneal cancer, or fallopian tube cancer.
Phase:
Phase 3
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborators:
European Organisation for Research and Treatment of Cancer - EORTC
Grupo Español de Investigación en Cáncer de Ovario
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Cisplatin
Paclitaxel
Topotecan